26 October 2018
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding.
Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.
It’s an approach the Big Pharma company also adopted last year when it hived off its rare disease assets into a company called SpringWorks, backed by Bain Capital and others including Double Impact, Orbimed and LifeArc.
The Cerevel spinoff “is similar [to SpringWorks], albeit on a larger scale in terms of number of assets, capital committed, and commercial potential,” explain Chris Gordon and Adam Koppel, M.D., Ph.D., managing directors at Bain Capital Private Equity and Bain Capital Life Sciences, respectively, who note there is also more cash in the offing if needed.
“It is a model that makes a lot of sense for pharma companies, if they can find the right partner,” they told FierceBiotech. This type of deal can push forward “assets that might not be optimally developed internally … while maintaining involvement and economic upside.”
Pfizer is retaining a 25% share in Cerevel, and two of its senior executives—Doug Giordano, senior VP of worldwide business development, and Morris Birnbaum, M.D., Ph.D., senior VP and chief scientific officer of internal medicine—will sit on the new company’s board alongside Gordon and Koppel. For now, there’s no word on who will fill the CEO role and other top positions.
Cerevel starts life with a pipeline headed by PF-06649751, a dopamine 1 partial agonist for Parkinson’s that is due to start a phase 3 study next year.
Following after are two phase 2-ready programs, including GABA 2/3 antagonist PF-06372865 for epilepsy and an M4 positive allosteric modulator that Cerevel will explore in “a psychosis-related indication,” according to Gordon and Koppel.
The remainder of Pfizer’s donated assets are all preclinical projects with “a diverse set of mechanisms [and] target indications currently in disease-modifying Parkinson’s, addiction/substance abuse disorder, psychosis, and neuroinflammation,” they noted.
Pfizer isn’t alone in deciding to downsize its direct involvement in central nervous system drug development, which tends to have a lower chance of success and higher costs than other therapeutic categories.
Other Big Pharma companies such as Sanofi, Johnson & Johnson, AstraZeneca and Merck have also cut back on CNS since its heyday in the late 20th century, when psychiatric drugs for diseases like schizophrenia and depression featured prominently among the top-selling medicines in the world, in favor of more lucrative areas such as cancer and diabetes
“When Pfizer made the decision to exit internal neuroscience research, we determined that the most effective way to maximize the potential value to patients of a promising clinical and preclinical portfolio would be to invest in external opportunities with high expertise and dedicated focus in CNS,” said Birnbaum.
“We are convinced that Cerevel represents such an opportunity and will continue to develop the Pfizer compounds, fulfilling our responsibility to patients and our goal to invest in biotech companies conducting promising neuroscience research in areas of urgent unmet need.”
31 October 2018
Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.
30 October 2018
Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.
29 October 2018
The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.
26 October 2018
Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.
We believe that Russian excellence in multi-disciplinary scientific and technological innovation, in synergy with the wave of entrepreneurial and creative talent now being unleashed with the rise of the Russian Millennial generation, will, against the backdrop of macroeconomic stability afforded by Russia’s vast natural resources, combine to make the world a much better place for everyone
We believe that most Russian companies, ideas, concepts and brands are enormously undervalued, not just in terms of their potential on the Russian markets, but in terms of their global potential. Our task is to identify this potential and execute against it, to world class standards of efficiency and effectiveness
In order to identify and unlock the potential value in the companies we work with, we have developed a holistic methodology which goes all the way from goals and strategies to the minute, concrete detail of day-to-day management operations
We work rapidly to develop goals and strategy, but in parallel we look for quick wins to generate early success and focus the employees, customers and partners on the company’s new mission and values and to demonstrate the immediate, short-term value we bring
Our success is your success. Our reward is based primarily on the quantifiable value we bring to the assets we manage and grow
Our expertise covers a wide range of industry sectors, geographic regions and functional specialisms. One of our key competitive differentiators is our ability to apply learning, experience, innovation and best practice from one sector to another and one country to another
In a rapidly globalizing business, social and political environment we uncompromisingly seek out business models that are the best in the world as the starting point for our work. Only in this way can we help our customers realize their true potential in a way which is both significant and sustainable
Our leading directors have decades of collective experience in multiple industries with public market accountability in realizing global concepts and adapting these to the realities and opportunities specific to Russia